CG Oncology, Inc. (NASDAQ:CGON) Receives $55.30 Consensus PT from Analysts

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has been given an average rating of "Buy" by the twelve research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $55.30.

Several equities analysts have recently commented on CGON shares. HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of CG Oncology in a report on Monday, April 28th. Wall Street Zen upgraded shares of CG Oncology from a "sell" rating to a "hold" rating in a report on Friday, June 27th. Morgan Stanley upped their price objective on shares of CG Oncology from $52.00 to $56.00 and gave the stock an "overweight" rating in a report on Tuesday, June 17th. Scotiabank initiated coverage on shares of CG Oncology in a report on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 price objective for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $75.00 target price on shares of CG Oncology in a research report on Monday, April 28th.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 2,000 shares of the company's stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $28.00, for a total transaction of $56,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Institutional Trading of CG Oncology

Several hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of CG Oncology by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company's stock worth $77,000 after acquiring an additional 398 shares during the period. Invesco Ltd. raised its holdings in shares of CG Oncology by 2.5% during the first quarter. Invesco Ltd. now owns 27,754 shares of the company's stock worth $680,000 after acquiring an additional 685 shares during the period. NEOS Investment Management LLC raised its holdings in shares of CG Oncology by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 8,329 shares of the company's stock worth $239,000 after acquiring an additional 817 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of CG Oncology by 6.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 15,270 shares of the company's stock worth $374,000 after acquiring an additional 930 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of CG Oncology by 0.4% during the first quarter. Massachusetts Financial Services Co. MA now owns 258,090 shares of the company's stock worth $6,321,000 after acquiring an additional 933 shares during the period. 26.56% of the stock is owned by institutional investors.

CG Oncology Stock Performance

Shares of NASDAQ CGON traded up $0.15 during trading on Friday, hitting $26.90. The company had a trading volume of 873,827 shares, compared to its average volume of 872,292. The company has a market cap of $2.05 billion, a P/E ratio of -17.81 and a beta of 0.86. CG Oncology has a 52 week low of $14.80 and a 52 week high of $40.47. The business's 50-day moving average is $26.10 and its 200 day moving average is $26.01.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.09). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 16.71%. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.53 million. On average, research analysts expect that CG Oncology will post -1.31 EPS for the current year.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.